End stage liver disease and liver cancer are major health concerns for individuals with hepatitis C virus (HCV) infection. Current therapies for HCV aim to halt and reverse the progression of liver injury. These therapies are based on interferon (IFN) and are expected to continue to be based on IFN for the foreseeable future. Both host and viral factors influence treatment outcome. Published data show that viral point mutations in the core gene are associated with treatment failure and insulin resistance. Of great interest, these same mutations (in codons 70 and 91) are associated with the development of liver cancer. These highly specific viral point mutations provide a unique opportunity to investigate HCV-related liver damage and treatment failure at the molecular level. We recently discovered that the disease-associated mutations in codons 70 and 91 have a profound effect on HCV gene expression: They alter the level of two newly identified viral proteins, 70 minicore protein and 91 minicore protein. In a major finding, we discovered that the disease-associated mutation in codon 91 enhances the internal initiation of protein synthesis at codon 91. Our data add to earlier evidence that HCV uses "divergent" modes of translation initiation to evade cellular antiviral defenses and to increase viral fitness. To account for minicore production, we propose that the core gene contains an extensive and highly conserved translational machine that promotes the internal initiation of protein synthesis at specific sites, driving minicore synthesis and enhancing IFN resistance and viral persistence. The impact of mutations in codons 70 and 91 on the IFN sensitivity of viruses and on the structure and function of minicore proteins will be investigated in Aim I. The properties of the translational machine and the effect of the disease-associated mutations on its activity will be determined in Aim II. Accomplishment of our Aims will fill fundamental gaps in the understanding of the HCV life cycle and provide basic information needed to design interventions to block the action of the translational machine and to inhibit the effects of the minicore proteins in patients.

Public Health Relevance

Clinical studies of liver disease patients with chronic hepatitis C virus (HCV) infection provide vital information about viral and host determinants of treatment outcome and disease progression. It is thus highly significant that clinical studies have identified two mutations in HCV that are strongly associated with treatment failure and the development of liver cancer. This project investigates the action of these mutations at the molecular level, with the ultimate goal of developing interventions to block the effects of the viral genes influenced by the disease- associated mutations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK090317-03
Application #
8323571
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2010-09-30
Project End
2015-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2012
Total Cost
$418,046
Indirect Cost
$170,881
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Patel, Neal; Bichoupan, Kian; Ku, Lawrence et al. (2016) Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World J Gastroenterol 22:2844-54
El-Shamy, Ahmed; Pendleton, Matthew; Eng, Francis J et al. (2016) Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients. Sci Rep 6:27025
Del Bello, David; Cha, Agnes; Sorbera, Maria et al. (2016) Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clin Infect Dis 62:1497-504
Hearn, Bevin; Chasan, Rachel; Bichoupan, Kian et al. (2015) Low adherence of HIV providers to practice guidelines for hepatocellular carcinoma screening in HIV/hepatitis B coinfection. Clin Infect Dis 61:1742-8
Hartman, Joshua; Bichoupan, Kian; Patel, Neal et al. (2015) Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. World J Gastroenterol 21:12430-8
Klepper, Arielle; Branch, Andrea D (2015) Macrophages and the Viral Dissemination Super Highway. EC Microbiol 2:328-336
El-Shamy, Ahmed; Eng, Francis J; Doyle, Erin H et al. (2015) A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol 63:1323-33
Saeed, Mohsan; Andreo, Ursula; Chung, Hyo-Young et al. (2015) SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524:471-5
Martel-Laferrière, V; Michel, A; Schaefer, S et al. (2015) Clinical characteristics of human immunodeficiency virus patients being referred for liver transplant evaluation: a descriptive cohort study. Transpl Infect Dis 17:527-35
Woodrell, Christopher; Weiss, Jeffrey; Branch, Andrea et al. (2015) Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. J Addict Med 9:405-10

Showing the most recent 10 out of 25 publications